ESC Guidance for the Diagnosis and Management of CVD during COVID-19

Over the past several weeks, I’ve had the opportunity to speak with many of you to understand how you are triaging and managing patients with suspected coronary artery disease in the COVID-19 era. One thing that has become abundantly clear is that as physicians, we won’t be returning to “business as usual.” As we consider how to best manage patients while increasing efficiency, and preserving resources such as PPE, I find the conversation returning to how a coronary CCTA-led pathway can play a critical role now and moving forward.

In light of this, I was highly encouraged to see the recent ESC guidance for the Diagnosis and Management of CV Disease during the COVID-19 Pandemic. This publication summarizes global learnings about COVID-related illness and how it impacts cardiovascular health.

Within this discussion, it provides quite direct guidance to prioritize CCTA in CAD diagnosis during the pandemic: “CT angiography should be preferred to non-invasive functional testing during [the] COVID-19 pandemic” (Table 13).

Key excerpts from the document explain the reasoning behind this clear directive:

Additionally, the ISCHEMIA trial’s influence on clinical decision making is clear within the discussion of Management and Treatment Pathways as a conservative pathway is prioritized for many patients.

In addition to the ESC guidance, a new guidance from SCAI/ ACC/ ACEP and an update from SCCT indicate that CCTA may be appropriate for helping physicians triage patients in the emergency room setting. In the SCAI/ACC/ACEP recommendation on AMI patients, the recommendation is to utilize CCTA if the echocardiography and ECG results are divergent. Similarly, the updated SCCT guidance recommends that utilizing CCTA in the ER setting may result in a meaningful change to patient management or outcomes.

While these publications are meant to provide guidance during this pandemic period, it is clear that some of the changes being recommended now will prove to be beneficial for patients and providers even after this pandemic subsides.

With clinicians now using more technology and digital solutions to gain efficiency, it seems reasonable to believe that the movement to CCTA for CAD diagnosis will be a change that stays, as it uniquely provides a combination of diagnostic confidence, prognostic insights, patient-provider safety, and increasing availability of CT-derived lesion-specific physiology.

Read the ESC Guidance

— A perspective from HeartFlow Chief Medical Officer, Campbell Rogers, MD
Bio | LinkedIn

Contact Us

*Required fields

Request the HeartFlow Analysis Near You

If you would like to request to have the HeartFlow Analysis available at a location near you, please submit your information below with details of the institution. We will share this information with the institution, but it will not guarantee HeartFlow will become available.

*Required fields

残念ながら、GDPR 規制により、この Web フォームを通じて求人への応募やキャリアに関する問い合わせを受け付けることはできません。弊社を通じてお申込みください 採用ページ. ご関心をお寄せいただきありがとうございます!

オンライン提出フォームから研究助成金を申請してください。

HeartFlow FFRCT 分析は、有資格の臨床医による臨床的に安定した症状のある冠状動脈疾患患者への使用を目的とした個別化された心臓検査です。 HeartFlow Analysis によって提供される情報は、資格のある臨床医が患者の病歴、症状、その他の診断検査、および臨床医の専門的判断と組み合わせて使用​​することを目的としています。

ハートフロー分析に関する追加の適応情報については、次のサイトをご覧ください。www.heartflow.com/indications.

さらに質問がある場合は、このメッセージを閉じてフォームに記入するか、サポート チームにお電話ください。: 877.478.3569.

The HeartFlow FFRCT Analysis is a personalized cardiac test indicated for use in clinically stable symptomatic patients with coronary artery disease by qualified clinicians. The information provided by the HeartFlow Analysis is intended to be used by qualified clinicians in conjunction with the patient’s history, symptoms, and other diagnostic tests, as well as the clinician’s professional judgement.

For additional indication information about the HeartFlow Analysis, please visit www.heartflow.com/indications.

If you have additional questions, close out of this message to complete our form or call our support team: 877.478.3569.

Please use our online submission form on the Clinical Research Page to apply for research grants.

Thank you for your interest!

Unfortunately, we cannot take job applications or career inquiries through this web form due to GDPR regulations. Please apply through our Careers Page. Thank you for your interest!

Campbell Rogers, M.D., F.A.C.C.

Executive Vice President and Chief Medical Officer

Campbell brings a wealth of experience to HeartFlow, where he serves as the Chief Medical Officer. Prior to joining HeartFlow, he was the Chief Scientific Officer and Global Head of Research and Development at Cordis Corporation, Johnson & Johnson, where he was responsible for leading investments and research in cardiovascular devices. Prior to Cordis, he was Associate Professor of Medicine at Harvard Medical School and the Harvard-M.I.T. Division of Health Sciences and Technology, and Director of the Cardiac Catheterization and Experimental Cardiovascular Interventional Laboratories at Brigham and Women’s Hospital. He served as Principal Investigator for numerous interventional cardiology device, diagnostic, and pharmacology trials, is the author of numerous journal articles, chapters, and books in the area of coronary artery and other cardiovascular diseases, and was the recipient of research grant awards from the NIH and AHA.

He received his A.B. from Harvard College and his M.D. from Harvard Medical School.